HC Wainwright Estimates Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Replimune Group in a report issued on Friday, May 23rd. HC Wainwright analyst R. Burns anticipates that the company will earn ($0.66) per share for the quarter. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2026 earnings at ($0.56) EPS and FY2026 earnings at ($2.89) EPS.

Separately, JPMorgan Chase & Co. upped their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Down 4.7%

Replimune Group stock opened at $8.35 on Monday. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The stock’s 50 day simple moving average is $8.63 and its two-hundred day simple moving average is $11.20. The firm has a market cap of $643.08 million, a PE ratio of -2.72 and a beta of 0.68.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period last year, the firm posted ($0.25) earnings per share.

Insider Activity

In other news, CEO Sushil Patel sold 25,105 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $202,346.30. Following the transaction, the chief executive officer now owns 343,576 shares in the company, valued at $2,769,222.56. This trade represents a 6.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Andrew Schwendenman sold 3,287 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. This trade represents a 4.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,907 shares of company stock worth $603,655 in the last quarter. Corporate insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in REPL. Boxer Capital Management LLC purchased a new position in shares of Replimune Group during the 4th quarter valued at approximately $21,754,000. Tang Capital Management LLC raised its stake in Replimune Group by 125.0% in the 4th quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company’s stock valued at $32,697,000 after purchasing an additional 1,500,000 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Replimune Group by 11.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company’s stock valued at $132,761,000 after purchasing an additional 1,083,633 shares during the last quarter. MPM Bioimpact LLC acquired a new position in Replimune Group in the 4th quarter valued at $11,504,000. Finally, RTW Investments LP raised its stake in Replimune Group by 82.1% in the 4th quarter. RTW Investments LP now owns 2,065,010 shares of the company’s stock valued at $25,007,000 after purchasing an additional 931,223 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.